###begin article-title 0
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
Evaluating the association of common APOA2 variants with type 2 diabetes
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
###xml 189 195 189 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
APOA2 is a positional and biological candidate gene for type 2 diabetes at the chromosome 1q21-q24 susceptibility locus. The aim of this study was to examine if HapMap phase II tag SNPs in APOA2 are associated with type 2 diabetes and quantitative traits in French Caucasian subjects.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 137 143 137 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
We genotyped the three HapMap phase II tagging SNPs (rs6413453, rs5085 and rs5082) required to capture the common variation spanning the APOA2 locus in our type 2 diabetes case-control cohort comprising 3,093 French Caucasian subjects. The association between these variants and quantitative traits was also examined in the normoglycaemic adults of the control cohort. In addition, meta-analysis of publicly available whole genome association data was performed.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 12 18 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
###xml 120 122 120 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 139 141 139 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 158 160 158 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 243 245 243 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 278 280 278 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 388 394 388 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
None of the APOA2 tag SNPs were associated with type 2 diabetes in the French Caucasian case-control cohort (rs6413453, P = 0.619; rs5085, P = 0.245; rs5082, P = 0.591). However, rs5082 was marginally associated with total cholesterol levels (P = 0.026) and waist-to-hip ratio (P = 0.029). The meta-analysis of data from 12,387 subjects confirmed our finding that common variation at the APOA2 locus is not associated with type 2 diabetes.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 66 72 66 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
The available data does not support a role for common variants in APOA2 on type 2 diabetes susceptibility or related quantitative traits in Northern Europeans.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
###xml 140 141 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 142 143 142 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 244 250 244 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
###xml 285 286 285 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 287 288 287 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 291 297 291 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 420 421 420 421 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
The APOA2 gene is located at chromosome 1q23.3, within the 1-LOD support interval of several genome-wide linkage scans for type 2 diabetes [1-3]. The peak of linkage in the French and Utah Caucasian genome-wide linkage scans was defined by the APOA2 intragenic microsatellite D1SAPO2 [1,3]. APOA2 encodes the apolipoprotein (apo) A-II, the second most abundant protein of the high-density lipoprotein (HDL) particles [4,5].
###end p 11
###begin p 12
###xml 37 43 37 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
###xml 139 140 139 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 141 142 141 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 292 293 292 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 384 390 384 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
###xml 432 438 432 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">HNF-4&#225;</italic>
###xml 506 512 506 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Apoa2 </italic>
###xml 543 544 543 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 0 15 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 31 36 <span type="species:ncbi:9606">human</span>
###xml 116 121 <span type="species:ncbi:9606">human</span>
###xml 162 167 <span type="species:ncbi:9606">human</span>
###xml 303 308 <span type="species:ncbi:9606">human</span>
###xml 332 335 <span type="species:ncbi:10116">rat</span>
###xml 378 383 <span type="species:ncbi:9606">human</span>
###xml 501 505 <span type="species:ncbi:10116">rats</span>
Transgenic mice overexpressing human APOA2 on a standard chow diet displayed lipid profiles similar to that seen in human type 2 diabetes [6,7]. Moreover, plasma human apoA-II levels were positively correlated with blood glucose levels and these animals displayed impaired glucose tolerance [7]. In the human HepG2 cell line and in rat primary hepatocytes, transcription of the human APOA2 transgene was upregulated by glucose in a HNF-4a-dependent fashion, whereas in streptozotocin-induced diabetic rats Apoa2 mRNA levels were not affected [7].
###end p 12
###begin p 13
###xml 24 30 24 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Apoa2 </italic>
###xml 163 164 163 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 448 449 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 18 23 <span type="species:ncbi:10090">mouse</span>
###xml 185 189 <span type="species:ncbi:10090">mice</span>
Overexpression of mouse Apoa2 contrastingly resulted in elevated levels of HDL and fasting blood glucose levels that were not significantly different from normal [8-10]. However, these mice appeared to be in a state of insulin resistance exhibiting two-fold raised plasma insulin levels, decreased triglyceride hydrolysis and increased fat deposition in adipose tissue, as well as delayed glucose clearance due to slower uptake in skeletal muscle [8]. Taken together, these findings point to a primary lipoprotein disturbance causing the development of several features of insulin resistance.
###end p 13
###begin p 14
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Apoa2 </italic>
###xml 188 190 188 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 41 45 <span type="species:ncbi:10090">mice</span>
On the other hand, homozygous Apoa2 null-mice had HDL level reductions of 70%, as well as lower free fatty acid, glucose and insulin levels, suggesting they may be insulin hypersensitive [11].
###end p 14
###begin title 15
###xml 29 35 29 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
Previous genetic analysis of APOA2 in type 2 diabetes
###end title 15
###begin p 16
###xml 34 40 34 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 579 581 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 406 414 <span type="species:ncbi:9606">patients</span>
Elbein and colleagues tested four APOA2 variants for association with T2D by TDT in 698 family members and in a very small case-control cohort of 247 subjects [12]. None of the SNPs exhibited association with T2D in the case-control cohort, nor were any of the SNP alleles over-transmitted in the TDT analysis. Certain microsatellite alleles, however, indicated a trend for excess transmission to diabetic patients and marginal association with triglyceride levels, FFA and fasting glucose, as well as first phase insulin response and insulin deposition index in model analysis [12].
###end p 16
###begin title 17
Methods
###end title 17
###begin title 18
Case-control subjects
###end title 18
###begin p 19
###xml 81 88 81 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 89 91 89 91 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 369 371 369 371 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 447 448 447 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 784 786 784 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 982 984 982 984 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 220 228 <span type="species:ncbi:9606">patients</span>
###xml 485 493 <span type="species:ncbi:9606">patients</span>
All subjects were of French Caucasian ancestry. Individuals identified by Sladek et al. [13] to lie outside the HapMap CEU ancestry cluster were excluded from the study. Type 2 diabetic case subjects were known diabetic patients receiving treatment for the condition. Normoglycaemic control subjects were selected to have a fasting blood glucose concentration <6.1 mM [14]. Case subjects were composed of: (i) 372 probands from diabetic families [3], recruited in Lille; and (ii) 1083 patients with a family history of T2D recruited at the Corbeil-Essonne Hospital. Control subjects were composed of: (i) 353 normoglycaemic parents from T2D families; (ii) 543 subjects from the SUVIMAX (Supplementation en Vitamines et Mineraux Antioxidant) prospective population-based cohort study [15]; and (iii) 742 subjects selected from the DESIR (Data from an Epidemiologic Study on the Insulin Resistance Syndrome) cohort, a large prospective study of insulin resistance in French subjects [16]. Informed consent was obtained from all subjects and the study was approved by the local ethics committees.
###end p 19
###begin title 20
Statistical power
###end title 20
###begin p 21
###xml 110 111 106 107 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 213 214 205 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 292 294 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
The case-control cohort comprised 1,455 type 2 diabetic subjects (age, 60 +/- 12 years; BMI, 29.0 +/- 6.0 kg/m2; male/female, 56:44%) and 1,638 normoglycaemic subjects (age, 54 +/- 13 years; BMI, 24.1 +/- 3.3 kg/m2; male/female, 43:57%). At alpha = 0.05, this sample size provided 91% power [17] to detect a type 2 diabetes susceptibility variant, assuming an allele frequency of 0.20, a disease prevalence of 0.1 and a heterozygote relative risk of 1.2 (multiplicative model).
###end p 21
###begin title 22
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
APOA2 tag SNP selection
###end title 22
###begin p 23
###xml 80 86 80 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
###xml 266 272 266 272 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
###xml 315 317 315 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
The genomic target region for tag SNP selection extended across the 3 kb NCBI36 APOA2 locus (chr1:159,458,001..159,461,000). A total of three HapMap phase II pairwise tagging SNPs (rs6413453, rs5085 and rs5082) were sufficient to tag the common variation across the APOA2 locus (HapMap Data Release 22/Apr07) with r2 and minor allele frequency (MAF) thresholds of 0.9 and 0.05, respectively.
###end p 23
###begin title 24
SNP genotyping
###end title 24
###begin p 25
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 268 270 268 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Genotyping was performed with the Sequenom MassARRAY iPLEX system [18]. SNP genotype frequencies were tested for accordance with Hardy-Weinberg equilibrium using chi-squared analysis. Quality control: all genotyped SNPs exhibited a call rate >99% and a Hardy-Weinberg P > 0.05, with well defined genotype clusters. In total, 19 case and 42 control subjects (1.97% of the total sample size) consistently failed genotyping and were removed from further analysis.
###end p 25
###begin title 26
Statistical analyses
###end title 26
###begin p 27
###xml 27 33 27 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 1096 1098 1096 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1154 1156 1154 1156 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1467 1469 1467 1469 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Q </italic>
###xml 1488 1490 1488 1490 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 1498 1500 1498 1500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1575 1577 1575 1577 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
To test for association of APOA2 SNPs with type 2 diabetes, chi-squared analysis of allele and genotype counts was performed. Pairwise SNP linkage disequilibrium (LD) values were calculated from the genotype data of the control cohort with Haploview (4.0) [19]. Quantitative anthropomorphic phenotypes, body mass index (BMI), weight and waist-hip ratio (WHR), as well as fasting serum levels of glucose, insulin, triacylglycerol (TG), total and high-density lipoprotein (HDL)-cholesterol, apolipoprotein A-I (APOA1) and apolipoprotein B (APOB), measured in 1,539 normoglycaemic subjects from the control cohort, were log transformed and adjusted for age, sex and BMI, as appropriate. SNPs were tested for association with adjusted quantitative traits using SPSS 15.0 with the ANOVA test under a codominant model. Quantitative trait association p-values are presented uncorrected for multiple testing. Combined analysis of association datasets was carried out by pooling of log-transformed odds ratios with the inverse variance method for the fixed-effects and random-effects models. The DIAGRAM [20] data included a sib-ship component from the DGI GWAS [21]; however, due to uncertainties about controlling for the effects of the relatedness of part of the study sample, we excluded these subjects and obtained data solely for unrelated subjects from the authors (E. Zeggini, personal communication, 23/04/2008). Inter-study heterogeneity was assessed with Cochran's Q statistic and the I2 metric [22]. These calculations were performed using R (2.5.1) statistical software [23].
###end p 27
###begin title 28
Results
###end title 28
###begin p 29
###xml 28 34 28 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
###xml 76 78 76 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 146 147 146 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 185 186 185 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 300 302 300 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 344 346 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
None of the three genotyped APOA2 tag SNPs showed evidence for association (P < 0.05) with type 2 diabetes in this French Caucasian cohort (Table 1; genotype counts see Additional file 1: Additional table 1). This finding is in agreement with the French GWAS [13], as well as a recent meta-analysis [20] of the DGI [21], FUSION [24] and WTCCC [25] genome-wide association studies.
###end p 29
###begin p 30
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
Association of APOA2 SNPs with type 2 diabetes.
###end p 30
###begin p 31
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 39 40 39 40 <sup xmlns:xlink="http://www.w3.org/1999/xlink">#</sup>
###xml 85 86 85 86 <sup xmlns:xlink="http://www.w3.org/1999/xlink">$</sup>
aSNP alleles are shown as major/minor. #Please refer to Methods section for details. $Imputed SNPs.
###end p 31
###begin title 32
Quantitative trait associations
###end title 32
###begin p 33
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
###xml 87 89 87 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 122 124 122 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 140 141 140 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 310 311 310 311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 384 386 384 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 527 528 527 528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
The APOA2 promoter SNP rs5082 was marginally associated with total cholesterol levels (P = 0.026) and waist-to-hip ratio (P = 0.029) (Table 2), and both associations exhibited a linear increase of the value of the quantitative phenotype from the common homozygote to the rare homozygote allele carriers (Table 3). The intronic variant rs6413453 was marginally associated with weight (P = 0.049), but given the small number of homozygote carriers of the minor allele (n = 13), it is likely that this is a spurious result (Table 2).
###end p 33
###begin p 34
###xml 15 21 15 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
Association of APOA2 SNPs with quantitative traits in French Caucasian control subjects.
###end p 34
###begin p 35
###xml 23 29 23 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
###xml 231 232 231 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
Association testing of APOA2 SNPs was carried out by ANOVA using SPSS (15.0). All traits were log transformed prior to correction for age, sex and BMI by linear regression, as appropriate. Trait means are presented anti-logged and P-values are reported without correction for multiple testing. BMI: body mass index; GLY0: fasting glucose; INS0: fasting insulin; TG: triacylglycerol; CHOL_TOT: total cholesterol; HDL: high-density lipoprotein-cholesterol; APOA1: apolipoprotein A-I; APOB: apolipoprotein B; WHR: waist-hip ratio.
###end p 35
###begin p 36
Distribution of quantitative trait values grouped by genotype for significant association results.
###end p 36
###begin p 37
Association testing was carried out by ANOVA comparison of trait means between genotype groups using SPSS (15.0). All traits were transformed prior to correction for age, sex and BMI by linear regression. The quantitative trait values displayed are the anti-logged trait means +/- SD.
###end p 37
###begin title 38
###xml 40 46 40 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
Linkage disequilibrium structure of the APOA2 genomic locus
###end title 38
###begin p 39
###xml 147 148 147 148 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 174 180 174 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
###xml 203 204 203 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 278 284 278 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
The structure of linkage disequilibrium across the three tag SNPs studied was consistent with HapMap phase II data. The levels of intermarker LD (r2) were negligible for the APOA2 locus (Additional file 1: Additional table 2). Therefore, no haplotype analysis was performed for APOA2 variants.
###end p 39
###begin title 40
###xml 17 23 17 23 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
Meta-analysis of APOA2 variants
###end title 40
###begin p 41
###xml 122 128 122 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
###xml 192 193 192 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S3">3</xref>
###xml 198 199 198 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S4">4</xref>
###xml 260 261 260 261 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Q</italic>
###xml 263 265 263 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 274 276 274 276 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
Meta-analysis combining publicly available data with our current study confirmed in over 12,000 subjects that none of the APOA2 tag SNPs were associated with type 2 diabetes (Additional files 2, 3, 4) and there appeared to be no study heterogeneity (Cochran's Q: P > 0.72; I2 = 0% for all variants). Consistent with the absence of inter-study heterogeneity the fixed and random effects models were identical for all three variants, therefore only the fixed effects are displayed.
###end p 41
###begin title 42
Discussion
###end title 42
###begin p 43
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
###xml 200 206 200 206 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
The APOA2 gene appeared to be a highly plausible candidate gene for type 2 diabetes susceptibility. In addition to defining the peak of linkage at chromosome 1q in French and Utah Caucasian families, APOA2 is the second most abundant lipoprotein component of HDL-cholesterol and has been implicated in the regulation of lipid metabolism and insulin sensitivity.
###end p 43
###begin p 44
###xml 78 84 78 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
###xml 249 255 249 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
###xml 347 353 347 353 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
Three HapMap phase II tag SNPs suffice to cover the common variation spanning APOA2 and genotyping of these variants demonstrated no association with type 2 diabetes. However, we cannot rule out the possibilities that distal common variants or rare APOA2 variants may be associated with type 2 diabetes. The quantitative trait association for the APOA2 variant rs5082 with total cholesterol levels was consistent with the physiological role of apoA-II; however, the strength of the association was marginal, as were the remaining, weaker associations with other continuous traits.
###end p 44
###begin p 45
###xml 40 42 40 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 127 128 127 128 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Meta-analysis of our data with DIAGRAM [20] consortium data, which was a mixture of directly genotyped and imputed SNPs (Table 1), corroborated our findings of no association with type 2 diabetes. It was also welcome to note that the data from imputed SNPs were in this context indistinguishable from that of the directly genotyped variants.
###end p 45
###begin title 46
Conclusion
###end title 46
###begin p 47
###xml 134 140 134 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APOA2 </italic>
Using a case-control cohort of over 3,000 subjects, we tested HapMap phase II tag SNPs that capture the common variation spanning the APOA2 genomic locus for association with type 2 diabetes, but failed to find any evidence supporting a contribution of this locus to type 2 diabetes susceptibility. This finding was confirmed in a combined analysis of more than 12,000 subjects.
###end p 47
###begin title 48
Abbreviations
###end title 48
###begin p 49
DGI: Diabetes Genetics Initiative; DIAGRAM: Diabetes Genetics Replication And Meta-analysis; FFA: free fatty acids; FUSION: Finland-United States Investigation of NIDDM Genetics; GWAS: Genome-wide association study; GWAS-MA: Genome-wide association study meta-analysis; WTCCC: Wellcome Trust Case-Control Consortium.
###end p 49
###begin title 50
Competing interests
###end title 50
###begin p 51
The authors declare that they have no competing interests.
###end p 51
###begin title 52
Authors' contributions
###end title 52
###begin p 53
KD participated in the design of the study, carried out the SNP genotyping, performed the analysis of the genotype data and drafted the manuscript. GC, MM, JT, SH and BB contributed to the design of the study. PF contributed to the study design and to drafting of the manuscript. FG contributed to the design of the study, the analysis of the genotype data and in drafting the manuscript. All authors read and approved the final manuscript.
###end p 53
###begin title 54
Pre-publication history
###end title 54
###begin p 55
The pre-publication history for this paper can be accessed here:
###end p 55
###begin p 56

###end p 56
###begin title 57
Supplementary Material
###end title 57
###begin title 58
Additional file 1
###end title 58
###begin p 59
###xml 0 26 0 26 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Additional tables 1 and 2.</bold>
Additional tables 1 and 2. Word document containing a a table listing the genotype counts for each SNP and a tabular representation of the LD structure across the locus.
###end p 59
###begin p 60
Click here for file
###end p 60
###begin title 61
Additional file 2
###end title 61
###begin p 62
###xml 0 69 0 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Forest plot graphical summary of the meta-analysis for SNP rs6413453.</bold>
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
Forest plot graphical summary of the meta-analysis for SNP rs6413453. Published data from the DIAGRAM [20] GWAS meta-analysis were combined with our data by pooling of log-transformed odds ratios with the inverse variance method using R (2.5.1) [23] software.
###end p 62
###begin p 63
Click here for file
###end p 63
###begin title 64
Additional file 3
###end title 64
###begin p 65
###xml 0 66 0 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Forest plot graphical summary of the meta-analysis for SNP rs5085.</bold>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
Forest plot graphical summary of the meta-analysis for SNP rs5085. Published data from the DIAGRAM [20] GWAS meta-analysis were combined with our data by pooling of log-transformed odds ratios with the inverse variance method using R (2.5.1) [23] software.
###end p 65
###begin p 66
Click here for file
###end p 66
###begin title 67
Additional file 4
###end title 67
###begin p 68
###xml 0 66 0 66 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Forest plot graphical summary of the meta-analysis for SNP rs5082.</bold>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 243 245 243 245 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
Forest plot graphical summary of the meta-analysis for SNP rs5082. Published data from the DIAGRAM [20] GWAS meta-analysis were combined with our data by pooling of log-transformed odds ratios with the inverse variance method using R (2.5.1) [23] software.
###end p 68
###begin p 69
Click here for file
###end p 69
###begin title 70
Acknowledgements
###end title 70
###begin p 71
This work was supported by a Wellcome Trust University Award to F.G. (GR065414MF) and a Medical Research Council Program Grant to PF (G0000477). We thank the referees for critically appraising draft versions of the manuscript.
###end p 71
###begin article-title 72
A genome-wide search for type 2 diabetes susceptibility genes in Utah Caucasians
###end article-title 72
###begin article-title 73
An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians
###end article-title 73
###begin article-title 74
Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24
###end article-title 74
###begin article-title 75
Distribution of apolipoprotein E between free and A-II complexed forms in very-low- and high-density lipoproteins: functional implications
###end article-title 75
###begin article-title 76
###xml 31 36 <span type="species:ncbi:9606">human</span>
Apoprotein (E-A-II) complex of human plasma lipoproteins. I. Characterization of this mixed disulfide and its identification in a high density lipoprotein subfraction
###end article-title 76
###begin article-title 77
###xml 18 23 <span type="species:ncbi:9606">human</span>
###xml 47 51 <span type="species:ncbi:10090">mice</span>
Overexpression of human apolipoprotein A-II in mice induces hypertriglyceridemia due to defective very low density lipoprotein hydrolysis
###end article-title 77
###begin article-title 78
###xml 42 47 <span type="species:ncbi:9606">human</span>
In vitro transcriptional induction of the human apolipoprotein A-II gene by glucose
###end article-title 78
###begin article-title 79
###xml 33 48 <span type="species:ncbi:10090">transgenic mice</span>
Studies with apolipoprotein A-II transgenic mice indicate a role for HDLs in adiposity and insulin resistance
###end article-title 79
###begin article-title 80
###xml 13 18 <span type="species:ncbi:10090">mouse</span>
###xml 65 80 <span type="species:ncbi:10090">transgenic mice</span>
Influence of mouse apolipoprotein A-II on plasma lipoproteins in transgenic mice
###end article-title 80
###begin article-title 81
###xml 19 34 <span type="species:ncbi:10090">transgenic mice</span>
Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II
###end article-title 81
###begin article-title 82
###xml 151 155 <span type="species:ncbi:10090">mice</span>
Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein A-II knockout mice suggest a complex role for apolipoprotein A-II in atherosclerosis susceptibility
###end article-title 82
###begin article-title 83
Evaluation of apolipoprotein A-II as a positional candidate gene for familial Type II diabetes, altered lipid concentrations, and insulin resistance
###end article-title 83
###begin article-title 84
A genome-wide association study identifies novel risk loci for type 2 diabetes
###end article-title 84
###begin article-title 85
Report of the expert committee on the diagnosis and classification of diabetes mellitus
###end article-title 85
###begin article-title 86
###xml 195 206 <span type="species:ncbi:9606">participant</span>
A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: the SU.VI.MAX study - design, methods, and participant characteristics. SUpplementation en VItamines et Mineraux AntioXydants
###end article-title 86
###begin article-title 87
[An epidemiologic survey from a network of French Health Examination Centres, (D.E.S.I.R.): epidemiologic data on the insulin resistance syndrome]
###end article-title 87
###begin article-title 88
Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits
###end article-title 88
###begin article-title 89
Automated genotyping using the DNA MassArray technology
###end article-title 89
###begin article-title 90
Haploview: analysis and visualization of LD and haplotype maps
###end article-title 90
###begin article-title 91
Meta-analysis of genome-wide association data and large-scale replication identifies several additional susceptibility loci for type 2 diabetes
###end article-title 91
###begin article-title 92
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels
###end article-title 92
###begin article-title 93
Measuring inconsistency in meta-analyses
###end article-title 93
###begin article-title 94
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants
###end article-title 94
###begin article-title 95
Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes
###end article-title 95

